Detail akcie Phathom Pharma Rg online

Business Summary: Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Phathom Pharmaceuticals Inc revenues increased from $25.6M to $117.5M. Net loss decreased 23% to $200.1M. Revenues reflect Voquezna Product increase from $18.3M to $117.5M. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 29% to $154.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$4.31 to -$2.77.